Bristol-Myers Squibb Company · NYSE:BMY
Bristol-Myers Squibb — ASCO GU 2024
12 slides from Bristol-Myers Squibb's conference presentation, Jan 25, 2024
Slide 1: BMS at ASCO GU 2024 AR LDD Phase 1 Highlights
BMS at ASCO GU 2024 AR LDD Phase 1 Highlights January 25th, 2024 Not for Product Promotional Use
Slide 2: Forward looking statements
Forward looking statements • This presentation (as well as the oral statements made with respect to information contained in this presentation) contains statements about Bristol-Myers Squibb Company’s (the “Company”) future financial results, plans, business development strategy, anticipated clinica
Slide 3: BMS at ASCO GU 2024 – AR LDD Phase 1 Data Highlights
BMS at ASCO GU 2024 – AR LDD Phase 1 Data Highlights Potential best-in-class oral androgen receptor (AR) ligand-directed degrader in mCRPC Promising efficacy & durability across AR status (e.g., wildtype, amplified, & mutant) in heavily pre-treated patients Well-tolerated with a manageable safety pr
Slide 4: AR LDD is the first example in solid tumors with our targeted protein degradation platform
AR LDD is the first example in solid tumors with our targeted protein degradation platform Expanded universe of targets Opportunity in Targeted Protein Degradation (e.g., scaffolding proteins, transcription factors) Drugged: Target with approved drugs (3%) Druggable: No 10 assets in clinical develop
Slide 5: Effective & tolerable treatment options needed in mCRPC
Effective & tolerable treatment options needed in Metastatic Castration Resistant Prostate Cancer (mCRPC) High unmet need remains in prostate cancer: • Expected U.S. mortality is ~35K1 men in 2023 • 5-year OS2 decreases from >97% to ~32.5% in the localized vs. metastatic setting Current SOC - ARPI2
Slide 6: AR LDD has shown promising PSA reduction in heavily pre-treated patients with mCRPC
AR LDD has shown promising PSA reduction in heavily pre-treated patients with mCRPC Prostate Specific Antigen (PSA) change from baseline by prior treatment Dose-dependent increase in PSA30 response from 400 to 900 mg BID PSA reduction across different pre-treatment regimens including prior ARPi & ch
Slide 7: AR LDD displayed efficacy across AR wildtype, amplification & mutant settings
AR LDD displayed efficacy across AR wildtype, amplification & mutant settings PSA change from baseline by AR status and dose (Part B)a Potentially paradigm- shifting MoA Promising clinical activity & ability to overcome resistance to ARPi, with best-in-class potential across AR status Data cutoff: N
Slide 8: AR LDD has shown signs of durable clinical benefit
AR LDD has shown signs of durable clinical benefit Figure 5. Treatment duration for individual patients in Part B Durable clinical benefit was observed for a substantial proportion of patients ~50% of patients in the 900mg BID group still on treatment after 6 months Median follow up for all patients
Slide 9: Phase 1 data supports a well tolerated & manageable safety profile
Phase 1 data supports a well tolerated & manageable safety profile Safety Profile* Treatment-Emergent Adverse Events (TEAE) Part A, Dose Part B, Dose All patients escalation (n = 27) expansion (n = 68) (N = 95) No Grade 4 treatment-related Any Grade Any Grade Any Grade adverse events (TRAEs) & no TE
Slide 10: AR LDD: Clinical development plan
AR LDD: Clinical development plan Current Status Next Steps Ph 1 data across Discussion of Continue dose Consider expanding into AR subgroups pivotal study optimization to earlier lines (e.g., presented at options with enable hormone sensitive) & ASCO GU health registrational explore synergistic Jan
Slide 11: Bristol Myers Squibb
(hi Bristol Myers Squibb”
Slide 12: Source & References
Source & References Poster Rathkopf et.al. First-in-human phase 1 study of CC-94676, a first-in-class androgen receptor (AR) ligand-directed degrader (LDD), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).// Abstract: 134, ASCO GU 2024 References 1. Chen Y, et al. Cell